title: Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.
abstract: An efficacious vaccine is needed to control Chlamydia trachomatis infection. In the murine model of Chlamydia muridarum genital infection, multifunctional mucosal CD4 T cells are the foundation for protective immunity, with antibody playing a secondary role. We previously identified four Chlamydia outer membrane proteins (PmpE, PmpF, PmpG and PmpH) as CD4 T cell vaccine candidates using a dendritic cell-based immunoproteomic approach. We also demonstrated that these four polymorphic membrane proteins (Pmps) individually conferred protection as measured by accelerated clearance of Chlamydia infection in the C57BL/6 murine genital tract model. The major outer membrane protein, MOMP is also a well-studied protective vaccine antigen in this system. In the current study, we tested immunogenicity and protection of a multisubunit recombinant protein vaccine consisting of the four Pmps (PmpEFGH) with or without the major outer membrane protein (MOMP) formulated with a Th1 polarizing adjuvant in C57BL/6, Balb/c and C3H mice. We found that C57BL/6 mice vaccinated with PmpEFGH+MOMP elicited more robust cellular immune responses than mice immunized with individual protein antigens. Pmps elicited more variable cellular immune responses than MOMP among the three strains of mice. The combination vaccine accelerated clearance in the three strains of mice although at different rates. We conclude that the recombinant outer membrane protein combination constitutes a promising first generation Chlamydia vaccine construct that should provide broad immunogenicity in an outbred population.
authors.affiliation: Vaccine Research Laboratory, British Columbia Centre for Disease Control Vancouver, Vancouver, BC, Canada.
authors.forename: Hong
authors.initials: H
authors.lastname: Yu
authors.affiliation: Vaccine Research Laboratory, British Columbia Centre for Disease Control Vancouver, Vancouver, BC, Canada.
authors.forename: Karuna P
authors.initials: KP
authors.lastname: Karunakaran
authors.affiliation: Vaccine Research Laboratory, British Columbia Centre for Disease Control Vancouver, Vancouver, BC, Canada.
authors.forename: Xiaozhou
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Vaccine Research Laboratory, British Columbia Centre for Disease Control Vancouver, Vancouver, BC, Canada. Electronic address: robert.brunham@bccdc.ca.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Brunham
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002690:Chlamydia Infections / Q000276:immunology / Q000517:prevention & control*; D023502:Chlamydia muridarum; D004195:Disease Models, Animal; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000276:immunology*
chemical_list: D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D011994:Recombinant Proteins
keywords: Chlamydia; Immunoproteomics; Recombinant protein; T cell antigens; Vaccine